BioSpace News Archive

Healthcare Trust of America, Inc. announced results for the quarter and year ended December 31, 2019..

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its fourth quarter and full year 2019 operational and financial results on Thursday, February 27, 2020 after the U.S. financial markets close

Urovant Sciences (Nasdaq: UROV) today reported financial results for the 2019 third fiscal quarter ended December 31, 2019.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2019.

Cassel’s capabilities amplify TASI Packaging Integrity Group’s customer-focused mission to help ensure packaging quality, protecting end-users worldwide

Atreca, Inc. announced that the first patient has been dosed in a Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers.

Seelos Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 6,666,667 shares of its common stock, at a price to the public of $0.75 per share.

Precision Optics Corporation, Inc., a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its second quarter fiscal year ended December 31, 2019.

Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced that it initiated dosing of the second cohort of its Phase 1 multiple ascending dose clinical trial of RGLS4326 for the treatment of autosomal dominant polycystic kidney disease.

VistaGen Therapeutics announced financial results for its fiscal year 2020 third quarter ended December 31, 2019.